Project Grant 2507437
Award Date
6/15/25
Completion Date
5/31/26
Dollars Obligated
$305K
Federal Agency
National Science Foundation
Awardee
Neucore Bio, Inc. (WH41WJ5LDF85)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
GRANDVIEW, OH 43212, USA
Similar Awards
The National Science Foundation (NSF) awarded a $274,966 Project Grant to Remedium Bio Inc., a for-profit organization, under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The grant supports the development of an adjustable gene therapy platform technology that will enable the use of genetic therapeutics beyond rare diseases, tackling large unmet clinical needs such as diabetes, osteoarthritis, and autoimmune diseases. The project aims to develop a dose-adjustable...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award for $275,000 will support the development of a plasmonic nanopore sensor device for quality control of adeno-associated viruses (AAVs) used in gene therapy. The proposed device will enable accurate characterization of AAV payload (single-stranded DNA, double-stranded DNA, or empty) at low, pre-scale-up concentrations to optimize formulations. The project aims to demonstrate the...
This SBIR Phase I award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $305,000 to Junipero Therapeutics, Inc. to develop an innovative gene therapy platform based on epigenome editing. The project aims to overcome key limitations of current gene therapies by harnessing oligonucleotide-based mechanisms to modulate gene activity in a precise and reversible manner. The proposed approach seeks to improve the safety,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $305,000 to Cellecho, Inc. supports the development of a microchip-based technology that leverages sound waves and electric fields to enable advanced cell engineering. The goal is to make complex cellular modifications, such as multiplex genome editing, more accessible for a wide range of users from students to experienced researchers. The technology aims to streamline processes...
This Project Grant award from the National Science Foundation (NSF) Engineering Program (CFDA 47.041) aims to develop scalable manufacturing processes for engineered extracellular vesicles (EVs) that can serve as targeted drug delivery vehicles. The $2.55M grant to Vanderbilt University, awarded on January 1, 2024, will fund research to harness cellular processes for optimizing EV production, cargo loading, and cellular uptake. The long-term goal is to establish a biomanufacturing platform for...
Through a $1,000,000 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program, Optimeos Life Sciences, Inc., a for-profit biotechnology company, is developing a non-viral platform for delivering mRNA-based gene therapies. The project aims to validate a polymer-lipid hybrid formulation that can safely and repeatedly deliver genetic instructions to patients with rare urea cycle disorders, overcoming limitations of current...
The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...
This $500,000 National Science Foundation project grant supports research to advance the biom anufacturing of extracellular vesicles through the integration of human induced pluripotent stem cell technology, genome engineering, and membrane nanofabrication. The primary recipient is Syracuse University, with Rochester Institute of Technology serving as a sub-awardee. Under the Biological Sciences program (CFDA 47.074), the grantees will work to generate a stable human iPSC line with enhanced EV...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award to Genexgen Inc., a small disadvantaged business, is providing $274,763 to develop an mRNA-based tolerogenic vaccine to address immune response challenges in viral-based gene therapies. The proposed solution aims to train the immune system to ignore antigens expressed in gene therapy treatments, enabling higher and more persistent therapeutic protein expression. This could...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....